Recent Investment Analysts’ Ratings Changes for Fortrea (FTRE)

A number of firms have modified their ratings and price targets on shares of Fortrea (NASDAQ: FTRE) recently:

• 11/11/2026 – Fortrea was downgraded by Mizuho from “neutral” to “underperform”. They now have a $19.00 price target on the stock, up from $16.00.
• 11/10/2026 – Fortrea was upgraded by Zacks Research from “strong sell” to “hold”.
• 11/2/2026 – Fortrea had its price target raised by TD Cowen from $23.00 to $26.00. They now have a “buy” rating on the stock.
• 10/31/2026 – Fortrea was downgraded by Wall Street Zen from “buy” to “hold”.
• 10/30/2026 – Fortrea had its “hold” rating reaffirmed by Jefferies Financial Group. They now have a $21.50 price target on the stock.
• 10/30/2026 – Fortrea had its price target raised by Truist Financial from $26.00 to $29.00. They now have a “buy” rating on the stock.
• 10/30/2026 – Fortrea had its price target raised by Citigroup from $22.00 to $27.00. They now have a “buy” rating on the stock.
• 10/30/2026 – Fortrea had its price target raised by Barclays from $23.00 to $26.00. They now have an “overweight” rating on the stock.
• 10/29/2026 – Fortrea is now covered by Citigroup. They set a “strong-buy” rating on the stock.
• 10/20/2026 – Fortrea had its price target raised by UBS Group from $22.00 to $24.00. They now have a “neutral” rating on the stock.
• 10/15/2026 – Fortrea had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 10/15/2026 – Fortrea was upgraded by Deutsche Bank from “hold” to “buy”. They now have a $25.00 price target on the stock, up from $20.00.
• 10/12/2026 – Fortrea was downgraded by Zacks Research from “hold” to “strong sell”.
• 10/10/2026 – Fortrea was upgraded by Wall Street Zen from “hold” to “buy”.
• 10/6/2026 – Fortrea was upgraded by Barclays from “equal weight” to “overweight”. They now have a $23.00 price target on the stock, up from $22.00.
• 9/30/2026 – Fortrea is now covered by UBS Group. They set a “neutral” rating and a $22.00 price target on the stock.
• 9/30/2026 – Fortrea was upgraded by UBS Group to “hold”.

Fortrea Stock Performance

Fortrea stock traded down $0.31 during midday trading on Friday, reaching $19.75. 336,291 shares of the stock traded hands, compared to its average volume of 1,560,334. The company has a current ratio of 0.97, a quick ratio of 0.97 and a debt-to-equity ratio of 1.94. The firm has a fifty day moving average price of $20.73 and a two-hundred day moving average price of $15.93. The firm has a market cap of $1.91 billion, a price-to-earnings ratio of -27.05, a PEG ratio of 0.51 and a beta of 1.88. Fortrea Holdings Inc. has a fifty-two week low of $8.55 and a fifty-two week high of $26.16.

Fortrea (NASDAQ:FTRE) last posted its earnings results on Thursday, October 29th. The company reported $0.28 EPS for the quarter, topping the consensus estimate of $0.22 by $0.06. The firm had revenue of $691.50 million during the quarter, compared to analysts’ expectations of $671.57 million. Fortrea had a negative net margin of 2.58% and a positive return on equity of 13.98%. On average, equities research analysts forecast that Fortrea Holdings Inc. will post 0.85 earnings per share for the current year.

Fortrea Holdings Inc. is a global contract research organization that provides clinical development and patient access services to pharmaceutical, biotechnology and medical device companies. The company supports the development of medicines and medical products from early research through later-stage clinical trials and post-approval studies. Its services include clinical trial planning and management, clinical pharmacology, patient recruitment and engagement, data management, regulatory support and related consulting.